Presenting Napo EU S.p.A.

Bringing crofelemer to the European market

Presenting Napo EU S.p.A.

Bringing crofelemer to the European market

About Napo EU

Napo EU S.p.A. is a recently incorporated subsidiary of Napo Pharmaceuticals, Inc., in Milan, Italy, that is focused on developing crofelemer for the European market. Crofelemer is marketed in the US by Napo Pharmaceuticals—a wholly owned subsidiary of Jaguar Health. Based in San Francisco, California, Jaguar is a commercial-stage pharmaceutical company focused on developing novel, plant-based, sustainably derived prescription medicines for people with gastrointestinal distress, specifically chronic, debilitating diarrhea.

About Napo EU

Napo EU S.p.A. is a recently incorporated subsidiary of Napo Pharmaceuticals, Inc., in Milan, Italy, that is focused on developing crofelemer for the European market. Crofelemer is marketed in the US by Napo Pharmaceuticals—a wholly owned subsidiary of Jaguar Health. Based in San Francisco, California, Jaguar is a commercial-stage pharmaceutical company focused on developing novel, plant-based, sustainably derived prescription medicines for people with gastrointestinal distress, specifically chronic, debilitating diarrhea.

Lead crofelemer indication targets

Lead crofelemer indication targets

Crofelemer is being investigated for symptomatic relief from diarrhea in acute-phase coronavirus disease 2019 (COVID-19) and the “long-hauler” COVID-19 recovery patient population.

Follow-on indication targets

Follow-on indication targets

Additional indications being investigated for crofelemer include:

  • HIV-related diarrhea
  • Cancer therapy–related diarrhea (currently being evaluated in a pivotal Phase 3 clinical trial in the US)
  • Irritable Bowel Syndrome (IBS) – Diarrhea Predominant (IBS‑D)
  • Idiopathic/functional diarrheaa
  • Supportive care for Inflammatory Bowel Disease (IBD)
  • Short Bowel Syndrome (SBS) & Congenital Diarrheal Disorders (CDD)

In addition, there are several other diarrheal indications for crofelemer under consideration that could extend the pipeline.

aInvestigator-initiated trial (IIT)

News & Events

News & Events

Learn more about recent news and upcoming events, and access additional resources for our lead indications

April 23, 2021

Jaguar Health Webcast: Napo EU Business Overview. Click below to register for the April 23 webinar.

March 30, 2021

Jaguar Health Announces Selection of Investment Bank and Nominated Advisor for Proposed Merger of the Dragon SPAC and Napo EU, Jaguar’s Italian Subsidiary

March 15, 2021

Jaguar Health Announces Incorporation of Napo EU Subsidiary in Italy